Optimer’s Dificid Could Pave A Path To Higher Prices For Antibiotics
Executive Summary
The drug developer appears to be making the case for premium pricing by differentiating fidaxomicin for its ability to sustain clinical response and cut costs associated with recurrence.
You may also be interested in...
Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors
The antibiotic company announced it is reviewing strategic options and that CEO Pedro Lichtinger has been replaced by Chairman Henry McKinnell. Hospital-based companies looking to beef up their portfolios with a commercial asset could drive a competitive process.
Antibiotic Recipe For High Prices: Outcomes Data, Targeted Use
Drug developers must show value, such as lower death rates, to justify high prices for antibiotics to treat drug resistant organisms, payers note during conference on the Limited Population Antibacterial Drug approval pathway.
Will New Antibiotic Incentives GAIN Investors’ Backing?
The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.